tacrine has been researched along with Parkinson Disease, Secondary in 5 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Excerpt | Relevance | Reference |
---|---|---|
") proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor." | 3.74 | Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. ( Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E, 2007) |
"Tacrine-treated rats showed a slight increase in the average initiation time for fast responses (i." | 1.30 | Motor dysfunction produced by tacrine administration in rats. ( Aberman, J; Carriero, DL; Gianutsos, G; Mayorga, AJ; Outslay, G; Salamone, JD, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tronci, E | 1 |
Simola, N | 1 |
Borsini, F | 1 |
Schintu, N | 1 |
Frau, L | 1 |
Carminati, P | 1 |
Morelli, M | 1 |
McSwain, ML | 1 |
Forman, LM | 1 |
Maany, I | 1 |
Carriero, DL | 1 |
Outslay, G | 1 |
Mayorga, AJ | 1 |
Aberman, J | 1 |
Gianutsos, G | 1 |
Salamone, JD | 1 |
Cabeza-Alvarez, CI | 1 |
González-Rubio, M | 1 |
García-Montero, R | 1 |
Alvarez-Tejerina, A | 1 |
5 other studies available for tacrine and Parkinson Disease, Secondary
Article | Year |
---|---|
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavi | 2007 |
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Therapy, Combination; Haloperidol; Hum | 1995 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson | 1996 |
Motor dysfunction produced by tacrine administration in rats.
Topics: Animals; Cholinesterase Inhibitors; Conditioning, Operant; Dose-Response Relationship, Drug; Dyskine | 1997 |
[Parkinsonian syndrome related to tacrine].
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Humans; Male; Parkinson Disease, Secon | 1999 |